ADARx Pharmaceuticals, Inc. (ADRX)
17.63
-0.05
(-0.28%)
USD |
NASDAQ |
Oct 23, 16:00
17.80
+0.17
(+0.96%)
After-Hours: 20:00
ADARx Pharmaceuticals Debt to Equity Ratio : 0.0647 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0647 |
| Date | Value |
|---|---|
| March 31, 2026 | 0.0556 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 456.33M |
| Total Liabilities (Quarterly) | 349.76M |
| Shareholders Equity (Quarterly) | 106.57M |
| Current Ratio | 12.98 |